AUTL logo

AUTL
Autolus Therapeutics Ltd - ADR

3,610
Mkt Cap
$375.26M
Volume
857,356.00
52W High
$2.70
52W Low
$1.15
PE Ratio
-1.31
AUTL Fundamentals
Price
$1.47
Prev Close
$1.41
Open
$1.42
50D MA
$1.50
Beta
1.35
Avg. Volume
1.82M
EPS (Annual)
-$1.08
P/B
2.81
Rev/Employee
$100,484.27
$578.99
Loading...
Loading...
News
all
press releases
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat·11d ago
News Placeholder
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround
Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity with a safety profile that could allow broader patient access, CEO...
MarketBeat·18d ago
News Placeholder
HC Wainwright Issues Positive Outlook for AUTL Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Autolus Therapeutics...
MarketBeat·19d ago
News Placeholder
Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)
Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday...
MarketBeat·22d ago
News Placeholder
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape...
MarketBeat·23d ago
News Placeholder
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·1mo ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at Mizuho
Mizuho lowered their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has gi...
MarketBeat·1mo ago
News Placeholder
Autolus Therapeutics' (AUTL) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Friday...
MarketBeat·1mo ago
<
1
2
...
>

Latest AUTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.